Chimeric Therapeutics (ASX:CHM) has announced positive initial results from its ADVENT-AML Phase 1B clinical trial. The trial, evaluating the combination of Chimeric’s CHM CORE-NK technology with standard AML treatment, has shown promising results in newly diagnosed AML patients who are ineligible for chemotherapy or stem cell transplant. As of May 15, 2025, two out of three evaluable patients achieved Complete Response with incomplete blood count recovery (CRi), indicating disease remission. The third patient experienced Stable Disease, meaning the cancer neither increased nor decreased in severity.
The ADVENT-AML trial (NCT05834244) is a first-of-its-kind frontline AML trial incorporating cell therapy. The trial combines azacitidine and venetoclax. The trial, conducted at MD Anderson Cancer Center, initially focused on relapsed/refractory AML subjects to determine safe dosage levels. No safety concerns were observed in that cohort. The current phase is enrolling newly diagnosed AML patients unsuitable for intensive treatments.
Dr. Rebecca McQualter, CEO of Chimeric Therapeutics, expressed enthusiasm about the potential of CORE-NK cells as an initial AML therapy. The company anticipates trial completion in the December 2025 quarter, contingent upon sufficient patient enrollment. The CORE-NK cells, manufactured and cryopreserved at Case Western Reserve University, offer “off-the-shelf” accessibility.
Chimeric Therapeutics is focused on developing innovative cell therapies for cancer treatment. Their diversified portfolio includes CAR-T cell therapies and allogeneic NK cell therapies, with four clinical-stage programs targeting various oncology indications, including gastrointestinal and neuroendocrine tumors, glioblastoma and blood cancers. This announcement underscores Chimeric’s position as a pioneer in the cell therapy sector, especially in developing frontline treatments for AML.
